SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001415889-14-003624
Filing Date
2014-11-19
Accepted
2014-11-19 16:36:00
Documents
10
Period of Report
2014-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q vsta10qsept302014.htm 10-Q 1204037
2 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER REQUIRED BY RULE 13A-14(A) UNDE ex31-1.htm EX-31.1 9271
3 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER REQUIRED BY RULE 13A-14(A) UNDE ex31-2.htm EX-31.2 9573
4 CERTIFICATION OF THE PRINCIPAL EXECUTIVE AND FINANCIAL OFFICERS REQUIRED BY RULE ex32.htm EX-32 6179
  Complete submission text file 0001415889-14-003624.txt   6303005

Data Files

Seq Description Document Type Size
5 vsta-20140930.xml EX-101.INS 1051266
6 vsta-20140930.xsd EX-101.SCH 56871
7 vsta-20140930_cal.xml EX-101.CAL 45388
8 vsta-20140930_def.xml EX-101.DEF 112813
9 vsta-20140930_lab.xml EX-101.LAB 278035
10 vsta-20140930_pre.xml EX-101.PRE 213307
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-244-9990
VistaGen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 000-54014 | Film No.: 141235939
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences